Related references
Note: Only part of the references are listed.Risk factors of central nervous system relapse in mantle cell lymphoma
Annarita Conconi et al.
LEUKEMIA & LYMPHOMA (2013)
CNS prophylaxis in diffuse large B-cell lymphoma: If, when, how and for whom?
Tali Siegal et al.
BLOOD REVIEWS (2012)
Flow Cytometric Immunophenotyping of Cerebrospinal Fluid Specimens
Fiona E. Craig et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study
Christiane Pott et al.
BLOOD (2010)
Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era
Juan-Manuel Sancho et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Mantle cell lymphoma with central nervous system involvement: frequency and clinical features
Saar Gill et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster et al.
BLOOD (2008)
What is the real risk of central nervous system involvement in mantle cell lymphoma?
Saar Gill et al.
LEUKEMIA & LYMPHOMA (2008)
[18F] fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma
Saar Gill et al.
CLINICAL LYMPHOMA & MYELOMA (2008)
Central nervous system involvement in mantle cell lymphoma
A. Ferrer et al.
ANNALS OF ONCOLOGY (2008)
Leukemic involvement is a common feature in mantle cell lymphoma
Ana Ferrer et al.
CANCER (2007)
A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus
Stefan Gesk et al.
BLOOD (2006)
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
C Pott et al.
BLOOD (2006)
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL):: a clinicopathological study from the European MCL Network
M Tiemann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma
LE Abrey et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
M Dreyling et al.
BLOOD (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology
U Hegde et al.
BLOOD (2005)
Cerebrospinal fluid involvement in mantle cell lymphoma
R Valdez et al.
MODERN PATHOLOGY (2002)
Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma
SL Chua et al.
LEUKEMIA & LYMPHOMA (2002)
Share Paper
